ArticleSexual medicine2025
Yimusake ameliorates corporal endothelial dysfunction by down-regulating the NLRP3 inflammasome-mediated NF-κB signaling pathway and inhibiting oxidative stress.
Article in Sexual medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yimusake, a traditional Uyghur medicine, can treat a variety of male diseases, but its effects and mechanisms on diabetes mellitus-induced erectile dysfunction (DMED) remain unclear. Aim: This study was designed to investigate the key cytokines and mechanisms by which Yimusake ameliorates corporal endothelial dysfunction in DMED rats. Methods: Firstly, normal rat penile corpus cavernosum endothelial cells (CCECs) were extracted and cultured Outcomes: Our study demonstrates that Yimusake can downregulate the NLRP3-mediated NF-κB signalling pathway, inhibiting oxidative stress and mitigating the endothelial damage in corpus cavernosum endothelial cells. Results: In the CCEC injury model established by 30 mM glucose, after incubation with Yimusake-containing drug serum and transfection with Sh-NLRP3 lentivirus, the expression of proteins and mRNAs related to the NF-κB signaling pathway mediated by NLRP3 was decreased, the expression of proteins related to oxidative stress was decreased, and the expression of proteins related to the endothelial function was increased. In DMED rats, after Yimusake and MCC950 interventions, the changes in pathway factors, oxidative stress levels, and endothelial function were consistent with the trends of Clinical Implications: Yimusake may ameliorate endothelial dysfunction in DMED by down-regulating the NLRP3 inflammasome-mediated NF-κB signaling pathway and inhibiting oxidative stress. Strengths and Limitations: Although we revealed that Yimusake can facilitate the restoration of the erectile tissue by improving endothelial function through inhibiting inflammation and oxidative stress, the effect was more significant with the combination of drugs, and the exact mechanism of action needs to be further explored. Conclusion: These findings demonstrate that DM exacerbates oxidative stress and endothelial damage in the corpus cavernosum through activation of the NLRP3 inflammasome-mediated NF-κB pathway, whereas Yimusake can inhibit oxidative stress and mitigate endothelial damage by downregulating this pathway, thereby facilitating the restoration of erectile tissue in rats with DMED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.